WO2009041613A1 - 抗体定常領域改変体 - Google Patents

抗体定常領域改変体 Download PDF

Info

Publication number
WO2009041613A1
WO2009041613A1 PCT/JP2008/067483 JP2008067483W WO2009041613A1 WO 2009041613 A1 WO2009041613 A1 WO 2009041613A1 JP 2008067483 W JP2008067483 W JP 2008067483W WO 2009041613 A1 WO2009041613 A1 WO 2009041613A1
Authority
WO
WIPO (PCT)
Prior art keywords
constant region
antibody constant
succeeded
stability
finding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/067483
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
Tomoyuki Igawa
Hirotake Shiraiwa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40511493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009041613(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2008304748A priority Critical patent/AU2008304748C1/en
Priority to EP20198500.9A priority patent/EP3789400A1/en
Priority to CA2700394A priority patent/CA2700394C/en
Priority to KR1020187033614A priority patent/KR102119108B1/ko
Priority to KR1020217040531A priority patent/KR102467302B1/ko
Priority to MX2010003450A priority patent/MX2010003450A/es
Priority to KR1020107008918A priority patent/KR101680906B1/ko
Priority to US12/680,082 priority patent/US9688762B2/en
Priority to BRPI0817273-0A priority patent/BRPI0817273B1/pt
Priority to EP08834649.9A priority patent/EP2194066B1/en
Priority to PL15200628T priority patent/PL3059246T3/pl
Priority to KR1020167032250A priority patent/KR101922788B1/ko
Priority to PH12014502106A priority patent/PH12014502106A1/en
Priority to EP18181757.8A priority patent/EP3415529B1/en
Priority to PH1/2018/501459A priority patent/PH12018501459B1/en
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to KR1020217006046A priority patent/KR102339457B1/ko
Priority to EP15200628.4A priority patent/EP3059246B1/en
Priority to HK11100811.4A priority patent/HK1146728B/xx
Priority to RU2010116278/10A priority patent/RU2526512C2/ru
Priority to JP2009534420A priority patent/JP5484060B2/ja
Priority to DK08834649.9T priority patent/DK2194066T3/en
Priority to MX2013009569A priority patent/MX342551B/es
Priority to CN2008801185811A priority patent/CN101874041B/zh
Priority to KR1020207015247A priority patent/KR102225009B1/ko
Priority to ES08834649.9T priority patent/ES2566957T3/es
Priority to PH1/2021/552811A priority patent/PH12021552811A1/en
Publication of WO2009041613A1 publication Critical patent/WO2009041613A1/ja
Priority to IL204537A priority patent/IL204537A0/en
Anticipated expiration legal-status Critical
Priority to ZA2010/02422A priority patent/ZA201002422B/en
Priority to US15/614,842 priority patent/US11332533B2/en
Priority to US17/720,937 priority patent/US12600789B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/JP2008/067483 2007-09-26 2008-09-26 抗体定常領域改変体 Ceased WO2009041613A1 (ja)

Priority Applications (30)

Application Number Priority Date Filing Date Title
PH1/2021/552811A PH12021552811A1 (en) 2007-09-26 2008-09-26 Modified antibody constant region
KR1020217006046A KR102339457B1 (ko) 2007-09-26 2008-09-26 항체 정상영역 개변체
CA2700394A CA2700394C (en) 2007-09-26 2008-09-26 Modified antibody constant region
KR1020187033614A KR102119108B1 (ko) 2007-09-26 2008-09-26 항체 정상영역 개변체
KR1020217040531A KR102467302B1 (ko) 2007-09-26 2008-09-26 항체 정상영역 개변체
MX2010003450A MX2010003450A (es) 2007-09-26 2008-09-26 Region constante de anticuerpo modificada.
KR1020107008918A KR101680906B1 (ko) 2007-09-26 2008-09-26 항체 정상영역 개변체
US12/680,082 US9688762B2 (en) 2007-09-26 2008-09-26 Modified antibody constant region
BRPI0817273-0A BRPI0817273B1 (pt) 2007-09-26 2008-09-26 Região constante de anticorpo humano com heterogeneidade cterminal reduzida e com amidação suprimida do aminoácido c-terminal, bem como anticorpos e composição farmacêutica
EP08834649.9A EP2194066B1 (en) 2007-09-26 2008-09-26 Modified antibody constant region
HK11100811.4A HK1146728B (en) 2007-09-26 2008-09-26 Modified antibody constant region
KR1020167032250A KR101922788B1 (ko) 2007-09-26 2008-09-26 항체 정상영역 개변체
PH12014502106A PH12014502106A1 (en) 2007-09-26 2008-09-26 Modified antibody constant region
EP18181757.8A EP3415529B1 (en) 2007-09-26 2008-09-26 Modified antibody constant region
PH1/2018/501459A PH12018501459B1 (en) 2007-09-26 2008-09-26 Modified antibody constant region
AU2008304748A AU2008304748C1 (en) 2007-09-26 2008-09-26 Modified antibody constant region
EP15200628.4A EP3059246B1 (en) 2007-09-26 2008-09-26 Modified antibody constant region
EP20198500.9A EP3789400A1 (en) 2007-09-26 2008-09-26 Modified antibody constant region
PL15200628T PL3059246T3 (pl) 2007-09-26 2008-09-26 Zmodyfikowany region stały przeciwciała
RU2010116278/10A RU2526512C2 (ru) 2007-09-26 2008-09-26 Модифицированная константная область антитела
JP2009534420A JP5484060B2 (ja) 2007-09-26 2008-09-26 抗体定常領域改変体
DK08834649.9T DK2194066T3 (en) 2007-09-26 2008-09-26 Modified constant region of an antibody
MX2013009569A MX342551B (es) 2007-09-26 2008-09-26 Region constante de anticuerpo modificada.
CN2008801185811A CN101874041B (zh) 2007-09-26 2008-09-26 抗体恒定区修饰体
KR1020207015247A KR102225009B1 (ko) 2007-09-26 2008-09-26 항체 정상영역 개변체
ES08834649.9T ES2566957T3 (es) 2007-09-26 2008-09-26 Región constante de anticuerpo modificado
IL204537A IL204537A0 (en) 2007-09-26 2010-03-16 Modified antibody constant region
ZA2010/02422A ZA201002422B (en) 2007-09-26 2010-04-07 Modified antibody constant region
US15/614,842 US11332533B2 (en) 2007-09-26 2017-06-06 Modified antibody constant region
US17/720,937 US12600789B2 (en) 2007-09-26 2022-04-14 Modified antibody constant region

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007250147 2007-09-26
JP2007-250147 2007-09-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/680,082 A-371-Of-International US9688762B2 (en) 2007-09-26 2008-09-26 Modified antibody constant region
US15/614,842 Division US11332533B2 (en) 2007-09-26 2017-06-06 Modified antibody constant region

Publications (1)

Publication Number Publication Date
WO2009041613A1 true WO2009041613A1 (ja) 2009-04-02

Family

ID=40511493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/067483 Ceased WO2009041613A1 (ja) 2007-09-26 2008-09-26 抗体定常領域改変体

Country Status (22)

Country Link
US (3) US9688762B2 (https=)
EP (4) EP3059246B1 (https=)
JP (9) JP5484060B2 (https=)
KR (6) KR101680906B1 (https=)
CN (1) CN101874041B (https=)
AR (4) AR068563A1 (https=)
AU (1) AU2008304748C1 (https=)
CA (5) CA3222170A1 (https=)
CL (1) CL2008002886A1 (https=)
DK (2) DK3059246T3 (https=)
ES (2) ES2566957T3 (https=)
IL (1) IL204537A0 (https=)
MX (2) MX2010003450A (https=)
MY (3) MY180713A (https=)
PE (1) PE20090711A1 (https=)
PH (3) PH12014502106A1 (https=)
PL (1) PL3059246T3 (https=)
RU (2) RU2526512C2 (https=)
SG (2) SG10201605394SA (https=)
TW (2) TWI464262B (https=)
WO (1) WO2009041613A1 (https=)
ZA (1) ZA201002422B (https=)

Cited By (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010064697A1 (ja) * 2008-12-05 2010-06-10 中外製薬株式会社 抗nr10抗体、およびその利用
WO2010107109A1 (ja) * 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
WO2010107110A1 (ja) * 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
WO2010106812A1 (en) * 2009-03-19 2010-09-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
WO2010107108A1 (ja) * 2009-03-19 2010-09-23 中外製薬株式会社 関節リウマチ治療剤
WO2010131733A1 (ja) 2009-05-15 2010-11-18 中外製薬株式会社 抗axl抗体
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
WO2011055550A1 (ja) 2009-11-05 2011-05-12 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
WO2011090088A1 (ja) 2010-01-20 2011-07-28 中外製薬株式会社 安定化抗体含有溶液製剤
WO2011092989A1 (ja) 2010-01-29 2011-08-04 東レ株式会社 ポリ乳酸系樹脂シート
JPWO2010064697A1 (ja) * 2008-12-05 2012-05-10 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
WO2012067176A1 (ja) 2010-11-17 2012-05-24 中外製薬株式会社 血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子
WO2012073985A1 (ja) * 2010-11-30 2012-06-07 中外製薬株式会社 細胞傷害誘導治療剤
WO2012115241A1 (ja) 2011-02-25 2012-08-30 中外製薬株式会社 FcγRIIb特異的Fc抗体
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
US8431127B2 (en) 2007-12-05 2013-04-30 Chugai Seiyaku Kabushiki Kaisha Method for treating pruritus comprising administering an NR10 antagonist
JPWO2011108714A1 (ja) * 2010-03-04 2013-06-27 中外製薬株式会社 抗体定常領域改変体
WO2013100120A1 (ja) 2011-12-28 2013-07-04 中外製薬株式会社 ヒト化抗Epiregulin抗体および当該抗体を有効成分として含む癌治療剤
WO2013118858A1 (ja) 2012-02-09 2013-08-15 中外製薬株式会社 抗体のFc領域改変体
US8562991B2 (en) 2008-09-26 2013-10-22 Chugai Seiyaku Kabushiki Kaisha Antibody molecules that bind to IL-6 receptor
JP2013539361A (ja) * 2010-07-29 2013-10-24 ゼンコア インコーポレイテッド 改変された等電点を有する抗体
WO2013187495A1 (ja) 2012-06-14 2013-12-19 中外製薬株式会社 改変されたFc領域を含む抗原結合分子
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
WO2014030728A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 FcγRIIb特異的Fc領域改変体
WO2014104165A1 (ja) 2012-12-27 2014-07-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
WO2014208482A1 (ja) 2013-06-24 2014-12-31 中外製薬株式会社 ヒト化抗Ｅｐｉｒｅｇｕｌｉｎ抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
JP2015500002A (ja) * 2011-10-10 2015-01-05 ゼンコア インコーポレイテッド 抗体を精製する方法
JP2015502373A (ja) * 2011-12-19 2015-01-22 シンイミューン ゲーエムベーハー 二重特異性抗体分子
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
WO2015046467A1 (ja) 2013-09-27 2015-04-02 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US9028821B2 (en) 2006-06-08 2015-05-12 Chugai Seiyaku Kabushiki Kaisha Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist
WO2015068847A1 (ja) 2013-11-11 2015-05-14 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
WO2015099165A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 等電点の低い抗体の精製方法
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
WO2015187779A1 (en) 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
WO2016098357A1 (en) 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies
US9539322B2 (en) 2010-05-28 2017-01-10 National University Corporation Hokkaido University Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody
US9605080B2 (en) 2014-11-21 2017-03-28 Bristol-Myers Squibb Company Antibodies against CD73
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
WO2017104783A1 (en) 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
US9725514B2 (en) 2007-01-23 2017-08-08 Shinshu University Chronic rejection inhibitor
WO2017217525A1 (en) 2016-06-17 2017-12-21 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9975966B2 (en) 2014-09-26 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing theraputic agent
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
JP2018529758A (ja) * 2015-08-07 2018-10-11 イマジナブ・インコーポレーテッド 標的分子に対する抗原結合コンストラクト
WO2019077092A1 (en) 2017-10-20 2019-04-25 F. Hoffmann-La Roche Ag METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
WO2019086362A1 (en) 2017-10-30 2019-05-09 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies
WO2019225568A1 (ja) 2018-05-21 2019-11-28 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
US10544227B2 (en) 2015-04-14 2020-01-28 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
WO2020032230A1 (ja) 2018-08-10 2020-02-13 中外製薬株式会社 抗ｃｄ１３７抗原結合分子およびその使用
JP2020504608A (ja) * 2016-12-23 2020-02-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善されたバイオアナリシス特性およびバイオプロセシング特性のための、治療用免疫グロブリンｇ４の設計
US10604561B2 (en) 2016-09-16 2020-03-31 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US10653791B2 (en) 2014-11-21 2020-05-19 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
US10717781B2 (en) 2008-06-05 2020-07-21 National Cancer Center Neuroinvasion inhibitor
US10774148B2 (en) 2015-02-27 2020-09-15 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
WO2020204152A1 (ja) * 2019-04-04 2020-10-08 小野薬品工業株式会社 二重特異性抗体
WO2020209318A1 (ja) 2019-04-10 2020-10-15 中外製薬株式会社 Ｆｃ領域改変抗体の精製方法
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JP2021500024A (ja) * 2017-10-18 2021-01-07 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
WO2021122733A1 (en) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
WO2021131021A1 (ja) 2019-12-27 2021-07-01 中外製薬株式会社 抗ｃｔｌａ－４抗体およびその使用
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
WO2021162020A1 (ja) 2020-02-12 2021-08-19 中外製薬株式会社 癌の治療に用いるための抗ｃｄ１３７抗原結合分子
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
US11180548B2 (en) 2015-02-05 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Methods of neutralizing IL-8 biological activity
WO2022025030A1 (ja) 2020-07-28 2022-02-03 中外製薬株式会社 新規改変型抗体を含む、針シールドを備えた針付プレフィルドシリンジ製剤
US11260125B2 (en) 2019-11-20 2022-03-01 Chugai Seiyaku Kabushiki Kaisha Anti-IL31RA antibody-containing formulations
WO2022045276A1 (ja) 2020-08-28 2022-03-03 中外製薬株式会社 ヘテロ二量体Ｆｃポリペプチド
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
JP2022060182A (ja) * 2020-10-02 2022-04-14 小野薬品工業株式会社 二重特異性抗体を有効成分として含む医薬組成物
EP4056993A1 (en) 2014-08-20 2022-09-14 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
WO2022263501A1 (en) 2021-06-18 2022-12-22 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
WO2022270611A1 (ja) 2021-06-25 2022-12-29 中外製薬株式会社 抗ｃｔｌａ－４抗体
WO2022270612A1 (ja) 2021-06-25 2022-12-29 中外製薬株式会社 抗ｃｔｌａ－４抗体の使用
WO2023057871A1 (en) 2021-10-04 2023-04-13 Novartis Ag Surfactant stabilizers
WO2023058723A1 (ja) 2021-10-08 2023-04-13 中外製薬株式会社 プレフィルドシリンジ製剤の調製方法
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
WO2023100975A1 (ja) 2021-12-01 2023-06-08 中外製薬株式会社 抗体含有製剤の調製方法
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2023210670A1 (ja) 2022-04-26 2023-11-02 中外製薬株式会社 医薬製剤含有フィルター内蔵シリンジ
JP2023168526A (ja) * 2018-07-10 2023-11-24 国立大学法人神戸大学 抗ＳＩＲＰα抗体
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11891432B2 (en) 2018-03-15 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2024034638A1 (ja) * 2022-08-10 2024-02-15 協和キリン株式会社 抗ｆｇｆ２３抗体又は該抗体断片
US12024560B2 (en) 2017-03-28 2024-07-02 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
WO2024214811A1 (ja) 2023-04-14 2024-10-17 中外製薬株式会社 タンパク質含有医薬製剤の安定化方法
US12415857B2 (en) 2021-06-25 2025-09-16 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
US12421322B2 (en) 2017-11-01 2025-09-23 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
US12428496B2 (en) 2017-12-07 2025-09-30 Chugai Seiyaku Kabushiki Kaisha Antibodies, compositions for use in detecting or capturing a polypeptide in a sample, and methods for detecting or capturing a polypeptide in a sample
EP4632120A2 (en) 2014-11-11 2025-10-15 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
US12460014B2 (en) 2016-04-28 2025-11-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12528863B2 (en) 2019-07-10 2026-01-20 Chugai Seiyaku Kabushiki Kaisha Claudin-6 binding molecules and uses thereof
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
US12583918B2 (en) 2019-04-17 2026-03-24 Tokyo Women's Medical University Therapeutic agent for urological cancer which is characterized by being administered with IL-6 inhibitor and CCR2 inhibitor in combination
US12600772B2 (en) 2018-01-31 2026-04-14 Motokazu Kato Therapeutic agent for asthma containing IL-6 inhibitor
US12600798B2 (en) 2017-03-31 2026-04-14 Public University Corporation Nara Medical University Medicinal composition usable for preventing and/or treating blood coagulation factor IX abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor VIII
US12617847B2 (en) 2010-11-30 2026-05-05 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043641A1 (ja) * 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
AU2007208678B2 (en) * 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
WO2009131702A2 (en) 2008-04-25 2009-10-29 Dyax Corp. Antibodies against fcrn and use thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
SMT201700023T1 (it) 2010-08-02 2017-03-08 Regeneron Pharma Topi che producono proteine leganti vl
GB201014033D0 (en) * 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
JP5721858B2 (ja) 2010-12-23 2015-05-20 ユーリタ アクチエンゲゼルシャフトＥｕｌｉｔｈａ Ａｇ 大きな面積にわたってナノ構造を製造するためのシステムおよび方法
ES2623912T3 (es) 2010-12-23 2017-07-12 Janssen Biotech, Inc. Mutantes FC de anticuerpo activo resistente a proteasa
JP2014511174A (ja) * 2011-02-07 2014-05-15 ネオトープ バイオサイエンシーズ リミテッド Ａｐｏｅ免疫療法
AU2012262007B2 (en) 2011-06-02 2017-06-22 Takeda Pharmaceutical Company Limited Fc receptor binding proteins
WO2013022855A1 (en) * 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP3597038B1 (en) * 2012-02-01 2021-04-21 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
EP2943512A4 (en) 2013-01-11 2016-06-01 California Inst Biomedical Res BOVINE FUSION ANTIBODY
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
KR102211837B1 (ko) 2013-01-14 2021-02-03 젠코어 인코포레이티드 신규한 이형이량체 단백질
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
EP3699195A3 (en) 2014-03-28 2020-11-04 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
US20170210818A1 (en) * 2014-06-06 2017-07-27 The California Institute For Biomedical Research Constant region antibody fusion proteins and compositions thereof
KR102614189B1 (ko) 2014-11-17 2023-12-18 리제너론 파아마슈티컬스, 인크. Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
PE20171324A1 (es) 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
JP7010854B2 (ja) 2016-06-14 2022-01-26 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
CN109715663B (zh) 2016-06-28 2022-11-25 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MY203000A (en) 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
IL268959B2 (en) 2017-02-28 2025-01-01 Seagen Inc Cystine-mutated antibodies, compositions containing them and uses thereof
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
KR102611853B1 (ko) 2017-06-30 2023-12-08 자임워크스 비씨 인코포레이티드 안정화된 키메라 fabs
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
IL275426B2 (en) 2017-12-19 2025-03-01 Xencor Inc Engineered il-2 fc fusion proteins
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
CN119080931A (zh) * 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CA3110513A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
AU2019355971B2 (en) 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CA3132185A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
US20220220210A1 (en) * 2019-03-29 2022-07-14 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
CN116323658A (zh) * 2020-09-28 2023-06-23 上海君实生物医药科技股份有限公司 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
CN117402255A (zh) * 2022-07-13 2024-01-16 南京优迈瑞保生物科技有限公司 抗人pd-l1和人ox40的双特异抗体及其应用
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058572A1 (en) 1998-05-08 1999-11-18 Cambridge University Technical Services Limited Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
WO2003039485A2 (en) 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
WO2005005604A2 (en) * 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2005056606A2 (en) * 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
US20050261229A1 (en) 1999-07-21 2005-11-24 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20060194280A1 (en) 2004-10-22 2006-08-31 Amgen Inc. Methods for refolding of recombinant antibodies
US20070280945A1 (en) 2006-06-02 2007-12-06 Sean Stevens High affinity antibodies to human IL-6 receptor

Family Cites Families (395)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US15133A (en) * 1856-06-17 Machine fob paring
US117097A (en) * 1871-07-18 Improvement in brick-machines
JPS5144499B1 (https=) 1970-08-29 1976-11-29
JPS5334319B2 (https=) 1971-12-28 1978-09-20
JPS5717624B2 (https=) 1974-04-17 1982-04-12
JPS5484060A (en) 1977-12-12 1979-07-04 Kyushu Sekisui Kogyo Treatment of raw *wakame* by using chlorella extract
US4324710A (en) 1980-10-02 1982-04-13 The Firestone Tire & Rubber Company Naturally occurring thermoplastic resins as a substitute for various petroleum-derived materials in rubber stocks
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
JPH0234615Y2 (https=) 1986-08-08 1990-09-18
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
FR2628833B1 (fr) 1988-03-18 1993-06-25 Pont Sur Sambre Ateliers Mecan Dispositif assurant le deconfinement d'une charge militaire contenant un explosif
US5126250A (en) * 1988-09-28 1992-06-30 Eli Lilly And Company Method for the reduction of heterogeneity of monoclonal antibodies
IL91778A (en) 1988-09-28 1994-10-07 Lilly Co Eli A method for reducing the heterogeneity of monoclonal antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB8916400D0 (en) 1989-07-18 1989-09-06 Dynal As Modified igg3
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5795965A (en) * 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ZA936260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
BR9204244A (pt) 1992-10-26 1994-05-03 Cofap Ferro fundido cinzento
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
CZ140195A3 (en) 1992-12-01 1996-06-12 Protein Desing Labs Humanized antibodies reacting with l-selectin
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
AU7967294A (en) 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
IL107742A0 (en) 1993-11-24 1994-02-27 Yeda Res & Dev Chemically-modified binding proteins
DE122009000068I2 (de) 1994-06-03 2011-06-16 Ascenion Gmbh Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5945311A (en) * 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
ES2384222T3 (es) 1994-10-07 2012-07-02 Chugai Seiyaku Kabushiki Kaisha Inhibición del crecimiento anómalo de células sinoviales utilizando un antagonista de IL-6 como principio activo
CN1306963C (zh) 1994-10-21 2007-03-28 岸本忠三 用于治疗il－6产生所致疾病的药物组合物
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US6485943B2 (en) 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
PT812136E (pt) 1995-02-28 2001-04-30 Procter & Gamble Preparacao de bebidas nao gaseificadas com estabilidade microbiana superior
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20020147326A1 (en) 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
ZA976326B (en) 1996-07-19 1998-02-03 Amgen Inc Analogs of cationic proteins.
US5990286A (en) 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
EP2322216A1 (en) 1997-03-21 2011-05-18 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US5980893A (en) 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
PT1004315E (pt) 1997-08-15 2008-07-09 Chugai Pharmaceutical Co Ltd Profilácticos e/ou medicamentos contendo anticorpos neutralizantes anti-receptor de il-6 para reduzir a excreção de proteínas urinárias no lúpus eritematoso sistémico
RU2221809C2 (ru) * 1997-10-03 2004-01-20 Тугаи Сейяку Кабусики Кайся Способ получения природного гуманизированного антитела
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
CN100374159C (zh) * 1998-03-17 2008-03-12 中外制药株式会社 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1069185T3 (da) 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
EP1105427A2 (en) * 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
HK1044159A1 (zh) * 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
EP2325316B8 (en) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
EP1325338A2 (en) * 2000-04-03 2003-07-09 Oxford GlycoSciences (UK) Limited Diagnosis and treatment of alzheimer's disease
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
PL366025A1 (pl) 2000-05-03 2005-01-24 Munich Biotech Ag Kationowe środki diagnostyczne, obrazujące i terapeutyczne, zasocjowane z uaktywnionymi miejscami wnaczyniach
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
CN1259973C (zh) 2000-10-25 2006-06-21 中外制药株式会社 含有il－6拮抗剂作为有效成分的牛皮癣的预防或治疗剂
JP4889187B2 (ja) * 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
DE60236735D1 (de) * 2001-04-13 2010-07-29 Biogen Idec Inc Antikörper gegen vla-1
KR100953520B1 (ko) * 2001-06-22 2010-04-21 츄가이 세이야꾸 가부시키가이샤 항글리피칸 3항체를 포함하는 항암제
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20030190705A1 (en) 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP3960855A1 (en) 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing proteins
DK1961811T3 (da) * 2002-01-18 2010-11-08 Zymogenetics Inc Cytokinligand til behandling af asthma og luftvejs-hyper-responsivitet
EP2840089A1 (en) * 2002-01-18 2015-02-25 ZymoGenetics, Inc. Cytokine receptor zcytor17 multimers
WO2003068801A2 (en) * 2002-02-11 2003-08-21 Genentech, Inc. Antibody variants with faster antigen association rates
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7736652B2 (en) 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
JP2006512891A (ja) 2002-04-18 2006-04-20 ジェネンコー・インターナショナル・インク 糸状菌における機能性抗体の生産
JP2004086862A (ja) 2002-05-31 2004-03-18 Celestar Lexico-Sciences Inc タンパク質相互作用情報処理装置、タンパク質相互作用情報処理方法、プログラム、および、記録媒体
WO2003107218A1 (ja) * 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 相互作用予測装置
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US20060141456A1 (en) * 2002-06-12 2006-06-29 Cynthia Edwards Methods and compositions for milieu-dependent binding of a targeted agent to a target
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
TW200407335A (en) * 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
WO2004016740A2 (en) 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
US7482436B2 (en) 2002-08-30 2009-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of antibody
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
GB0224082D0 (en) 2002-10-16 2002-11-27 Celltech R&D Ltd Biological products
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
DK2270048T3 (en) * 2002-12-24 2016-01-18 Rinat Neuroscience Corp Anti-NGF antibodies and methods for their use
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7223393B2 (en) 2003-02-07 2007-05-29 Pdl Biopharma, Inc Amphiregulin antibodies and their use to treat cancer and psoriasis
US20040223970A1 (en) * 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
NZ542134A (en) 2003-03-04 2009-06-26 Alexion Pharma Inc Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JP2007525438A (ja) 2003-03-24 2007-09-06 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
JP2004321100A (ja) 2003-04-25 2004-11-18 Rikogaku Shinkokai ＩｇＧのＦｃ領域を含むタンパク質の変異体
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2004106375A1 (en) * 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
JP2007526220A (ja) 2003-06-05 2007-09-13 ジェネンテック・インコーポレーテッド Ｂ細胞疾患の併用療法
WO2004113387A2 (en) 2003-06-24 2004-12-29 Merck Patent Gmbh Tumour necrosis factor receptor molecules with reduced immunogenicity
JP2005101105A (ja) 2003-09-22 2005-04-14 Canon Inc 位置決め装置、露光装置、デバイス製造方法
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
MXPA06003768A (es) 2003-10-17 2006-06-23 Chugai Pharmaceutical Co Ltd Agente terapeutico para el mesotelioma.
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
PL1691837T3 (pl) * 2003-12-10 2012-11-30 Squibb & Sons Llc IP-10 przeciwciała i ich zastosowanie
KR101225299B1 (ko) 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
EP1697748A4 (en) 2003-12-22 2007-07-04 Centocor Inc METHODS FOR GENERATING MULTIMEDIA MOLECULES
CN1922316B (zh) 2003-12-25 2011-03-23 协和发酵麒麟株式会社 抗cd40抗体突变体
ES2305886T3 (es) * 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
ATE464908T1 (de) 2004-02-11 2010-05-15 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
WO2005090405A1 (ja) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６受容体に対するヒト型化抗体のサブタイプ
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
KR20070035482A (ko) 2004-03-24 2007-03-30 추가이 세이야쿠 가부시키가이샤 인터로킨-6 안타고니스트를 활성성분으로 함유하는내이장해 치료제
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
WO2005112564A2 (en) 2004-04-15 2005-12-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Germline and sequence variants of humanized antibodies and methods of making and using them
EP2194064A1 (en) 2004-05-13 2010-06-09 Eli Lilly & Company FGF-21 fusion proteins
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Ｔａｇ-72에 대한 인간화 항체
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
CA2572133A1 (en) 2004-06-25 2006-01-12 Medimmune, Inc. Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
CA2572917C (en) 2004-07-06 2012-04-03 Bioren Inc. Look-through mutagenesis for developing altered polypeptides with enhanced properties
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
AU2005285347A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
WO2006028936A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US7572456B2 (en) 2004-09-13 2009-08-11 Macrogenics, Inc. Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US20080233131A1 (en) 2004-09-14 2008-09-25 Richard John Stebbings Vaccine
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
WO2006050166A2 (en) 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
AU2005335714B2 (en) * 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006065208A1 (en) 2004-12-14 2006-06-22 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
US8728828B2 (en) 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
WO2006071877A2 (en) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
PT1831258E (pt) 2004-12-28 2016-01-07 Univ Genova Anticorpos monoclonais contra nkg2a
EP1699826B1 (en) 2005-01-05 2009-03-11 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
US8716451B2 (en) 2005-01-12 2014-05-06 Kyowa Hakko Kirin Co., Ltd Stabilized human IgG2 and IgG3 antibodies
EP1858925A2 (en) * 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
EP1858924A1 (en) 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
US7700099B2 (en) * 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
PT1876236E (pt) * 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Anticorpos para substituição da função do factor de coagulação sanguínea viii
CN101193910A (zh) 2005-04-15 2008-06-04 健泰科生物技术公司 HGFβ链变体
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP1885755A4 (en) 2005-05-05 2009-07-29 Univ Duke CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASES
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
JP5224580B2 (ja) 2005-06-10 2013-07-03 中外製薬株式会社 ｓｃ（Ｆｖ）２部位特異的変異体
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
CN101627054A (zh) 2005-07-11 2010-01-13 马克罗基因公司 用人源化抗cd16a抗体治疗自身免疫疾病的方法
PL2573114T3 (pl) * 2005-08-10 2016-10-31 Identyfikacja i inżynieria przeciwciał z wariantami regionów FC oraz sposoby ich stosowania
PL2407486T3 (pl) 2005-08-19 2018-05-30 Wyeth Llc Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
EP1789435B1 (en) 2005-09-12 2010-02-24 Industry Foundation of Chonnam National University A method for production of mature natural killer cell
WO2007041317A2 (en) * 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
WO2007043641A1 (ja) 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
EP2749571A3 (en) * 2006-01-10 2014-08-13 ZymoGenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31RA and OSMRb antagonists
SG10201400426XA (en) * 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
AU2007208678B2 (en) 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
JP4294082B2 (ja) * 2006-03-23 2009-07-08 協和発酵キリン株式会社 ヒトトロンボポエチン受容体に対するアゴニスト抗体
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
JP5754875B2 (ja) * 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
TWI422387B (zh) 2006-05-25 2014-01-11 Glaxo Group Ltd 免疫球蛋白
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
ES2429407T3 (es) * 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
ES2415655T3 (es) * 2006-06-15 2013-07-26 The Board Of Trustees Of The University Of Arkansas Anticuerpos monoclonales que reconocen selectivamente Metanfetamina y compuestos similares a Metanfetamina
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
TWI438208B (zh) 2007-01-23 2014-05-21 中外製藥股份有限公司 抑制慢性排斥反應之藥劑
US20110236374A1 (en) * 2007-01-24 2011-09-29 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
US7919594B2 (en) * 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
JPWO2008114733A1 (ja) 2007-03-16 2010-07-01 協和発酵キリン株式会社 抗Ｃｌａｕｄｉｎ−４抗体
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
EP2144931A2 (en) 2007-04-04 2010-01-20 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
WO2008145141A1 (en) 2007-05-31 2008-12-04 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
EP2174667B1 (en) 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
EP2031064A1 (de) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
ES3006441T3 (en) * 2007-09-14 2025-03-18 Amgen Inc Homogeneous antibody populations
WO2009041734A1 (ja) 2007-09-26 2009-04-02 Kyowa Hakko Kirin Co., Ltd. ヒトトロンボポエチン受容体に対するアゴニスト抗体
MX2010003329A (es) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de il-6.
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
US8497355B2 (en) 2007-09-28 2013-07-30 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma
RU2490025C2 (ru) 2007-10-02 2013-08-20 Чугаи Сейяку Кабусики Кайся Терапевтические средства, используемые против реакции трансплантат против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2203180B1 (en) 2007-10-22 2012-11-21 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
AU2008321835B2 (en) * 2007-11-15 2014-11-20 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
CA2708065C (en) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
TW201634479A (zh) 2007-12-05 2016-10-01 中外製藥股份有限公司 抗ｎｒ１０抗體及其應用
HUE026846T2 (en) 2007-12-18 2016-08-29 Bioalliance Cv Antibodies to Recognize Carbohydrate-Containing Epitope on CD43 and CEA Expressed on Cancer Cells and Procedures for their Use
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
KR20160070165A (ko) 2008-02-08 2016-06-17 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
KR102057826B1 (ko) * 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
CA2728243C (en) 2008-06-05 2020-03-10 Chugai Seiyaku Kabushiki Kaisha Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CN108610416B (zh) 2008-10-13 2022-01-14 生物医学研究所 登革热病毒中和抗体及其用途
JP5913980B2 (ja) 2008-10-14 2016-05-11 ジェネンテック， インコーポレイテッド 免疫グロブリン変異体及びその用途
KR20110112307A (ko) 2008-11-25 2011-10-12 앨더 바이오파마슈티컬즈, 인코포레이티드 알부민을 상승시키고 및／또는 ｃｒｐ를 낮추는 ｉｌ­６의 길항제
WO2010064090A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Process for the modulation of the antagonistic activity of a monoclonal antibody
AR074438A1 (es) 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
KR20160062207A (ko) 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
EP2389386A4 (en) 2009-01-12 2013-11-06 Ge Healthcare Bio Sciences Ab affinity chromatography
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP2826789A1 (en) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
KR20120024763A (ko) * 2009-05-15 2012-03-14 추가이 세이야쿠 가부시키가이샤 항ａｘｌ 항체
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US10150808B2 (en) * 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
EP2903181B1 (en) 2009-12-18 2016-11-16 Electronics and Telecommunications Research Institute Method for sending/receiving data in a wireless packet communication system in which there is simultaneous communication with a plurality of terminals
CA2785414C (en) 2009-12-25 2019-01-22 Tomoyuki Igawa Polypeptide modification method for purifying polypeptide multimers
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
CA2787783A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
WO2011091181A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
ES2602971T3 (es) 2010-03-02 2017-02-23 Kyowa Hakko Kirin Co., Ltd. Composición de anticuerpo modificado
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
JP5932670B2 (ja) 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
US9162161B2 (en) 2010-03-31 2015-10-20 Jsr Corporation Filler for affinity chromatography
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
KR20190120439A (ko) 2010-11-08 2019-10-23 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US9376486B2 (en) 2010-12-14 2016-06-28 National University Of Singapore Human monoclonal antibody with specificity for Dengue virus serotype 1 E protein and uses thereof
WO2012132067A1 (ja) 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
EP2699263A4 (en) 2011-04-20 2014-12-24 Liquidating Trust METHOD FOR REDUCING AN UNWANTED IMMUNE RESPONSE TO A FOREIGN-LIKE IN A HUMAN PATIENT WITH ANTI-CD4 ANTIBODIES OR CD4-BINDING FRAGMENTS THEREOF OR CD4-BINDING MOLECULES
JP5729817B2 (ja) 2011-06-29 2015-06-03 日本電信電話株式会社 動画像符号化装置、動画像復号装置、動画像符号化方法、動画像復号方法、動画像符号化プログラム及び動画像復号プログラム
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
RU2014117505A (ru) 2011-09-30 2015-11-10 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула для ускорения удаления антигенов
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
WO2013089647A1 (en) 2011-12-16 2013-06-20 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
EP3517548A1 (en) 2012-03-13 2019-07-31 NovImmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
EP2832856A4 (en) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd ANTI-LAMP5 ANTIBODIES AND USE THEREOF
US9821050B2 (en) 2012-04-02 2017-11-21 The University Of North Carolina At Chapel Hill Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
US9556254B2 (en) 2012-05-14 2017-01-31 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cross-reactive antibodies against dengue virus and uses thereof
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
EP2857419B1 (en) 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
MX366886B (es) 2012-08-07 2019-07-30 Massachusetts Inst Technology Anticuerpos anti-virus del dengue y usos de los mismos.
US9540449B2 (en) 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
WO2014038686A1 (ja) 2012-09-10 2014-03-13 株式会社カネカ 吸着体
US9714291B2 (en) 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
EP2914634B1 (en) 2012-11-02 2017-12-06 Zymeworks Inc. Crystal structures of heterodimeric fc domains
WO2015089492A2 (en) 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
WO2014145159A2 (en) 2013-03-15 2014-09-18 Permeon Biologics, Inc. Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
US20140377253A1 (en) 2013-03-15 2014-12-25 Abbvie Biotherapeutics Inc. Fc variants
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
JP2016538275A (ja) 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
KR20160119806A (ko) 2014-02-11 2016-10-14 메사추세츠 인스티튜트 오브 테크놀로지 신규한 온전한 범위의 항-뎅기 항체
CN106211773B (zh) 2014-02-11 2021-09-03 威特拉公司 用于登革病毒的抗体分子及其应用
GB201413086D0 (en) 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
JP6630036B2 (ja) 2014-09-30 2020-01-15 Jsr株式会社 標的物の精製方法、及び、ミックスモード用担体
CN107406094B (zh) 2014-10-31 2020-04-14 北极星工业有限公司 用于控制车辆的系统和方法
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
WO2016148653A1 (en) 2015-03-17 2016-09-22 Agency For Science, Technology And Research A serotype cross-reactive, dengue neutralizing antibody and uses thereof
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
GB201610162D0 (en) 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN112119090B (zh) 2018-03-15 2023-01-13 中外制药株式会社 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
UA128549C2 (uk) 2019-12-27 2024-08-07 Чугаі Сейяку Кабусікі Кайся Антитіло до ctla-4 та його застосування
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
AR126220A1 (es) 2021-06-25 2023-09-27 Chugai Pharmaceutical Co Ltd Anticuerpo anti-ctla-4
TWI879694B (zh) 2021-06-25 2025-04-01 日商中外製藥股份有限公司 抗ctla-4抗體的用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058572A1 (en) 1998-05-08 1999-11-18 Cambridge University Technical Services Limited Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
US20050261229A1 (en) 1999-07-21 2005-11-24 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2003039485A2 (en) 2001-11-08 2003-05-15 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
WO2005005604A2 (en) * 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2005056606A2 (en) * 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
US20060194280A1 (en) 2004-10-22 2006-08-31 Amgen Inc. Methods for refolding of recombinant antibodies
US20070280945A1 (en) 2006-06-02 2007-12-06 Sean Stevens High affinity antibodies to human IL-6 receptor

Non-Patent Citations (54)

* Cited by examiner, † Cited by third party
Title
AJ CORDOBA; BJ SHYONG; D BREEN; RJ HARRIS: "Nonenzymatic hinge region fragmentation of antibodies in solution", J. CHROMATOGR. B. ANAL. TECHNOL. BIOMED. LIFE SCI., vol. 818, 2005, pages 115 - 121
ANN. HEMATOL., vol. 76, no. 6, 1998, pages 231 - 48
ARMOUR K. L: "Recombinant human IgG molecules lacking Fcy receptor I binding and monocyte triggering activities", EUR. J. IMMUNOL., vol. 29, 1999, pages 2613 - 2624, XP002501617 *
ARMOUR KL; CLARK MR; HADLEY AG; WILLIAMSON LM: "Recombinant human IgG molecules lacking Fegamma receptor I binding and monocyte triggering activities", EUR. J. IMMUNOL., vol. 29, no. 8, 1999, pages 2613 - 24
BIAN H. ET AL.: "Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE", METHODS, vol. 34, 2004, pages 468 - 475, XP027231794 *
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 255, 1999, pages 444 - 450
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 308, 2003, pages 94 - 100
BIRNEY ET AL., NUCLEIC ACIDS RES., vol. 34, 2006, pages D556 - 61
CANCER RES., vol. 53, no. 4, 1993, pages 851 - 6
CHAU LA; TSO JY; MELROSE J; MADRENAS J: "HuM291 (Nuvion), a humanized Fc receptor-nonbinding antibody against CD3, anergizes peripheral blood T cells as partial agonist of the T cell receptor", TRANSPLANTATION, vol. 71, no. 7, 2001, pages 941 - 50
CHU GC; CHELIUS D; XIAO G; KHOR HK; COULIBALY S; BONDARENKO PV: "Accumulation of Succinimide in a Recombinant Monoclonal Antibody in Mildly Acidic Buffers Under Elevated Temperatures", PHARM. RES., vol. 24, no. 6, 2007, pages 1145 - 56
COLE MS; ANASETTI C; TSO JY: "Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells", J. IMMUNOL., vol. 159, no. 7, 1997, pages 3613 - 21
DATTA-MANNAN A. ET AL.: "Monoclonal Antibody Clearance", J.BIOL.CHEM., vol. 282, January 2007 (2007-01-01), pages 1709 - 1717, XP008132028 *
DHIMAN N. ET AL.: "Gene expression microarrays:a 21st century tool for directed vaccine design", VACCINE, vol. 20, 2002, pages 22 - 30, XP004305110 *
EUR. J. IMMUNOL., vol. 29, no. 8, 1999, pages 2613 - 24
F. L. GRAHAM; J. VAN DER EB, VIROLOGY, vol. 52, 1973, pages 456 - 467
GESSNER JE; HEIKEN H; TAMM A; SCHMIDT RE: "The IgG Fc receptor family", ANN. HEMATOL., vol. 76, no. 6, 1998, pages 231 - 48
GHETIE V. ET AL.: "Incresing the serum persistence of an IgG fragment by random mutagenesis", NATURE BIOTECHNOLOGY, vol. 15, 1997, pages 637 - 640, XP000876642 *
GHETIE V; POPOV S; BORVAK J; RADU C; MATESOI D; MEDESAN C; OBER RJ; WARD ES: "Increasing the serum persistence of an IgG fragment by random mutagenesis", NAT. BIOTECHNOL., vol. 15, no. 7, 1997, pages 637 - 40
GUYRE PM; GRAZIANO RF; GOLDSTEIN J; WALLACE PK; MORGANELLI PM; WARDWELL K; HOWELL AL: "Increased potency of Fc-receptor-targeted antigens", CANCER IRNMUNAL. IMMUNOTHER., vol. 45, no. 3-4, 1997, pages 146 - 8
HASHIMOTO-GOTOH, T.; MIZUNO, T.; OGASAHARA, Y.; NAKAGAWA, M.: "An oligodeoxyribonucleotide-directed dual amber method for site-directed mutagenesis", GENE, vol. 152, 1995, pages 271 - 275
HINTON PR; XIONG JM; JOHLFS MG; TANG MT; KELLER S; TSURUSHITA N: "An engineered human IgG1 antibody with longer serum half-life", J. IRNMUNOL., vol. 176, no. 1, 2006, pages 346 - 56
INT. IMMUNOL., vol. 18, no. 12, 2006, pages 1759 - 69
J. BIOL. CHEM., vol. 282, no. 3, 2007, pages 1709 - 17
J. EXP. MED., vol. 180, no. 6, 1994, pages 2377 - 2381
J. IMMUNOL., vol. 169, no. 9, 2002, pages 5171 - 80
J. IMMUNOL., vol. 176, no. 1, 2006, pages 346 - 56
J. PHARM. SCI., vol. 97, no. 4, 2008, pages 1414 - 26
JANICE M REICHERT; CLARK J ROSENSWEIG; LAURA B FADEN; MATTHEW C DEWITZ: "Monoclonal antibody successes in the clinic", NATURE BIOTECHNOLOGY, vol. 23, 2005, pages 1073 - 1078
JOHNSON K. A. ET AL.: "Cation exchange-HPLC and mass spectrometry reveal C-terminal amidation of IgGl heavy chain", ANALYTICAL BIOCHEMISTRY, vol. 360, January 2007 (2007-01-01), pages 75 - 83, XP005725305 *
JOHNSON KA; PAISLEY-FLANGO K; TANGARONE BS; PORTER TJ; ROUSE JC: "Cation exchange-HPLC and mass spectrometry reveal C-terminal amidation of an IgGI heavy chain", ANAL. BIOCHEM., vol. 360, no. 1, 2007, pages 75 - 83
JOURNAL OF VIROLOGY, vol. 75, 2001, pages 2803 - 2809
KRAMER W.; FRITZ H. J.: "Oligonucleotidc:-directed construction of mutations via gapped duplex DNA Methods", ENZYMOL., vol. 154, 1987, pages 350 - 367
KRAMER, W.; DRUTSA, V.; JANSEN, H. W.; KRAMER, B.; PFLUGFELDER, M.; FRITZ, H. J.: "The gapped duplex DNA approach to oligonucleotide-directed mutation construction", NUCLEIC ACIDS RES., vol. 12, 1984, pages 9441 - 9456
KUNKEL, T. A.: "Rapid and efficient site-specific mutagenesis without phenotypic selection", PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488 - 492
METHODS, vol. 34, no. 4, 2004, pages 468 - 75
MOL. IMMUNOL., vol. 30, no. 1, 1993, pages 105 - 8
MOL. IRNMUNOL., vol. 30, no. 1, 1993, pages 105 - 8
NAT. BIOTECHNOL., vol. 25, no. 12, 2007, pages 1369 - 72
NAT. REV. IMMUNOL., vol. 7, no. 9, 2007, pages 715 - 25
NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 773 - 777
NATURE BIOTECHNOLOGY, vol. 23, 2005, pages 1159 - 1169
NATURE BIOTECHNOLOGY, vol. 25, 2007, pages 63 - 565
P. L. FELGNER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413
PAVLOU AK; BELSEY MJ: "The therapeutic antibodies market to 2008", EUR, J. PHARM. BIOPHARM., vol. 59, no. 3, 2005, pages 389 - 96
PROC. NATL. ACAD. SCI. USA., vol. 99, no. 26, 2002, pages 16899 - 16903
PROC. NATL.. ACAD. SCI. USA., vol. 103, no. 49, 2006, pages 18709 - 14
QLODOLFO ET AL., IMMUNOLOGY LETTERS, 1998, pages 47 - 52
R. W. MALONE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 6077
REDDY MP; KINNEY CA; CHAIKIN MA; PAYNE A; FISHMAN-LOBELL J; TSUI P; DAL MONTE PR; DOYLE ML; BRIGHAM-BURKE MR; ANDERSON D: "Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4", J. IMMUNOL., vol. 164, no. 4, 2000, pages 1925 - 33
SHIRE SJ; SHAHROKH Z; LIU J: "Challenges in the development of high protein concentration formulations", J. PHARM. SCI., vol. 93, no. 6, 2004, pages 1390 - 402
STRAND V; KIMBERLY R; ISAACS JD: "Biologic therapies in rheumatology: lessons learned, future directions", NAT. REV. DRUG DISCOV., vol. 6, no. 1, 2007, pages 75 - 92
THIES M.J.W. ET AL.: "The Alternatively Folded State of the Antibody CH3 Domain", J.MOL.BIOL., vol. 309, 2001, pages 1077 - 1085, XP004479201 *
ZOLLER, M. J.; SMITH, M.: "Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors.", METHODS ENZYMOL., vol. 100, 1983, pages 468 - 500

Cited By (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168344B2 (en) 2005-03-31 2021-11-09 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US10934344B2 (en) 2006-03-31 2021-03-02 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US12473375B2 (en) 2006-03-31 2025-11-18 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
US9028821B2 (en) 2006-06-08 2015-05-12 Chugai Seiyaku Kabushiki Kaisha Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist
US9745378B2 (en) 2006-06-08 2017-08-29 Chugai Seiyaku Kabushiki Kaisha Antibodies that bind to cytokine receptor NR10
US9725514B2 (en) 2007-01-23 2017-08-08 Shinshu University Chronic rejection inhibitor
US12116414B2 (en) 2007-09-26 2024-10-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US12600789B2 (en) 2007-09-26 2026-04-14 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
US11332533B2 (en) 2007-09-26 2022-05-17 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US9828429B2 (en) 2007-09-26 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US12122840B2 (en) 2007-09-26 2024-10-22 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies
US8431127B2 (en) 2007-12-05 2013-04-30 Chugai Seiyaku Kabushiki Kaisha Method for treating pruritus comprising administering an NR10 antagonist
US10472623B2 (en) 2008-04-11 2019-11-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US9890377B2 (en) 2008-04-11 2018-02-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US11359194B2 (en) 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11371039B2 (en) 2008-04-11 2022-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US10717781B2 (en) 2008-06-05 2020-07-21 National Cancer Center Neuroinvasion inhibitor
US10662245B2 (en) 2008-09-26 2020-05-26 Chugai Seiyaku Kabushiki Kaisha Methods of reducing IL-6 activity for disease treatment
US8562991B2 (en) 2008-09-26 2013-10-22 Chugai Seiyaku Kabushiki Kaisha Antibody molecules that bind to IL-6 receptor
WO2010064697A1 (ja) * 2008-12-05 2010-06-10 中外製薬株式会社 抗nr10抗体、およびその利用
JPWO2010064697A1 (ja) * 2008-12-05 2012-05-10 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
WO2010107109A1 (ja) * 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
WO2010107108A1 (ja) * 2009-03-19 2010-09-23 中外製薬株式会社 関節リウマチ治療剤
EP3674317A1 (en) * 2009-03-19 2020-07-01 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2826789A1 (en) * 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10253091B2 (en) 2009-03-19 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10066018B2 (en) 2009-03-19 2018-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2010107110A1 (ja) * 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
WO2010106812A1 (en) * 2009-03-19 2010-09-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9340615B2 (en) 2009-05-15 2016-05-17 Chugai Seiyaku Kabushiki Kaisha Anti-AXL antibody
WO2010131733A1 (ja) 2009-05-15 2010-11-18 中外製薬株式会社 抗axl抗体
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
WO2011055550A1 (ja) 2009-11-05 2011-05-12 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
EP3275898A1 (en) 2009-11-05 2018-01-31 Osaka University Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
US11612562B2 (en) 2010-01-20 2023-03-28 Chugai Seiyaku Kabushiki Kaisha Solution preparation containing stabilized antibody
WO2011090088A1 (ja) 2010-01-20 2011-07-28 中外製薬株式会社 安定化抗体含有溶液製剤
EP3378486A2 (en) 2010-01-20 2018-09-26 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing liquid formulations
EP3892292A2 (en) 2010-01-20 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing liquid formulations
EP4442277A2 (en) 2010-01-20 2024-10-09 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing liquid formulations
US10022319B2 (en) 2010-01-20 2018-07-17 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing liquid formulations
WO2011092989A1 (ja) 2010-01-29 2011-08-04 東レ株式会社 ポリ乳酸系樹脂シート
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
JPWO2011108714A1 (ja) * 2010-03-04 2013-06-27 中外製薬株式会社 抗体定常領域改変体
US9539322B2 (en) 2010-05-28 2017-01-10 National University Corporation Hokkaido University Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody
JP2013539361A (ja) * 2010-07-29 2013-10-24 ゼンコア インコーポレイテッド 改変された等電点を有する抗体
WO2012067176A1 (ja) 2010-11-17 2012-05-24 中外製薬株式会社 血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子
EP3318633A1 (en) 2010-11-17 2018-05-09 Chugai Seiyaku Kabushiki Kaisha Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US11066483B2 (en) 2010-11-30 2021-07-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
CN109160951A (zh) * 2010-11-30 2019-01-08 中外制药株式会社 细胞毒诱导治疗剂
WO2012073985A1 (ja) * 2010-11-30 2012-06-07 中外製薬株式会社 細胞傷害誘導治療剤
EP2647707B1 (en) 2010-11-30 2018-09-12 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
JP2020078335A (ja) * 2010-11-30 2020-05-28 中外製薬株式会社 細胞傷害誘導治療剤
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
JP2018093879A (ja) * 2010-11-30 2018-06-21 中外製薬株式会社 細胞傷害誘導治療剤
JP2020202879A (ja) * 2010-11-30 2020-12-24 中外製薬株式会社 細胞傷害誘導治療剤
US12479929B2 (en) 2010-11-30 2025-11-25 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
JPWO2012073985A1 (ja) * 2010-11-30 2014-05-19 中外製薬株式会社 細胞傷害誘導治療剤
EP3434767A1 (en) * 2010-11-30 2019-01-30 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
KR20190028811A (ko) * 2010-11-30 2019-03-19 추가이 세이야쿠 가부시키가이샤 세포상해 유도 치료제
KR102244173B1 (ko) 2010-11-30 2021-04-26 추가이 세이야쿠 가부시키가이샤 세포상해 유도 치료제
US12617847B2 (en) 2010-11-30 2026-05-05 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US12522669B2 (en) 2010-11-30 2026-01-13 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
EP3604330A1 (en) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
WO2012115241A1 (ja) 2011-02-25 2012-08-30 中外製薬株式会社 FcγRIIb特異的Fc抗体
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
EP4011913A1 (en) 2011-06-30 2022-06-15 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
JP7022162B2 (ja) 2011-10-10 2022-02-17 ゼンコア インコーポレイテッド 抗体を精製する方法
JP2020099337A (ja) * 2011-10-10 2020-07-02 ゼンコア インコーポレイテッド 抗体を精製する方法
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JP2015500002A (ja) * 2011-10-10 2015-01-05 ゼンコア インコーポレイテッド 抗体を精製する方法
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
JP2015502373A (ja) * 2011-12-19 2015-01-22 シンイミューン ゲーエムベーハー 二重特異性抗体分子
WO2013100120A1 (ja) 2011-12-28 2013-07-04 中外製薬株式会社 ヒト化抗Epiregulin抗体および当該抗体を有効成分として含む癌治療剤
EP4624490A2 (en) 2012-02-09 2025-10-01 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
WO2013118858A1 (ja) 2012-02-09 2013-08-15 中外製薬株式会社 抗体のFc領域改変体
WO2013187495A1 (ja) 2012-06-14 2013-12-19 中外製薬株式会社 改変されたFc領域を含む抗原結合分子
EP4310191A2 (en) 2012-06-14 2024-01-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
EP3721900A1 (en) 2012-08-24 2020-10-14 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc region variant
EP3597747A1 (en) 2012-08-24 2020-01-22 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
WO2014030728A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 FcγRIIb特異的Fc領域改変体
WO2014104165A1 (ja) 2012-12-27 2014-07-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
EP3783017A1 (en) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
WO2014208482A1 (ja) 2013-06-24 2014-12-31 中外製薬株式会社 ヒト化抗Ｅｐｉｒｅｇｕｌｉｎ抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
WO2015046467A1 (ja) 2013-09-27 2015-04-02 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US11124576B2 (en) 2013-09-27 2021-09-21 Chungai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
WO2015068847A1 (ja) 2013-11-11 2015-05-14 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
EP4461751A2 (en) 2013-11-11 2024-11-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
EP4671270A2 (en) 2013-12-27 2025-12-31 Chugai Seiyaku Kabushiki Kaisha METHOD FOR THE PURIFICATION OF ANTIBODY WITH A LOW ISOELECTRIC POINT
WO2015099165A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 等電点の低い抗体の精製方法
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
WO2015187779A1 (en) 2014-06-03 2015-12-10 Xbiotech, Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
EP3970747A2 (en) 2014-06-03 2022-03-23 XBiotech Inc. Compositions and methods for treating and preventing staphylococcus aureus infections
EP4056993A1 (en) 2014-08-20 2022-09-14 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
US11001643B2 (en) 2014-09-26 2021-05-11 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
US9975966B2 (en) 2014-09-26 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing theraputic agent
EP4632120A2 (en) 2014-11-11 2025-10-15 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
US10167343B2 (en) 2014-11-21 2019-01-01 Bristol-Myers Squibb Company Antibodies against CD73
US11352440B2 (en) 2014-11-21 2022-06-07 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
US9605080B2 (en) 2014-11-21 2017-03-28 Bristol-Myers Squibb Company Antibodies against CD73
US10100129B2 (en) 2014-11-21 2018-10-16 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
US10653791B2 (en) 2014-11-21 2020-05-19 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EP4600372A2 (en) 2014-12-19 2025-08-13 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016098357A1 (en) 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US12595299B2 (en) 2015-02-05 2026-04-07 Chugai Seiyaku Kabushiki Kaisha FC variants
US11180548B2 (en) 2015-02-05 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Methods of neutralizing IL-8 biological activity
US10774148B2 (en) 2015-02-27 2020-09-15 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
US12359001B2 (en) 2015-04-01 2025-07-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
US11773173B2 (en) 2015-04-14 2023-10-03 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
US10544227B2 (en) 2015-04-14 2020-01-28 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
US12441804B2 (en) 2015-04-14 2025-10-14 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
JP2020100668A (ja) * 2015-08-07 2020-07-02 イマジナブ・インコーポレーテッド 標的分子に対する抗原結合コンストラクト
JP7026613B2 (ja) 2015-08-07 2022-02-28 イマジナブ・インコーポレーテッド 標的分子に対する抗原結合コンストラクト
JP2022095755A (ja) * 2015-08-07 2022-06-28 イマジナブ・インコーポレーテッド 標的分子に対する抗原結合コンストラクト
JP7097923B2 (ja) 2015-08-07 2022-07-08 イマジナブ・インコーポレーテッド 標的分子に対する抗原結合コンストラクト
JP2018529758A (ja) * 2015-08-07 2018-10-11 イマジナブ・インコーポレーテッド 標的分子に対する抗原結合コンストラクト
JP7487250B2 (ja) 2015-08-07 2024-05-20 イマジナブ・インコーポレーテッド 標的分子に対する抗原結合コンストラクト
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
WO2017104783A1 (en) 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US12460014B2 (en) 2016-04-28 2025-11-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
WO2017217525A1 (en) 2016-06-17 2017-12-21 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US11053308B2 (en) 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
US11780912B2 (en) 2016-08-05 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of IL-8 related diseases
US12516115B2 (en) 2016-08-05 2026-01-06 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of IL-8 related diseases
US10844113B2 (en) 2016-09-16 2020-11-24 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US12187786B2 (en) 2016-09-16 2025-01-07 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US10604561B2 (en) 2016-09-16 2020-03-31 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US11780908B2 (en) 2016-09-16 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant FC regions, and methods of use
JP7062669B2 (ja) 2016-12-23 2022-05-06 ブリストル－マイヤーズ スクイブ カンパニー 改善されたバイオアナリシス特性およびバイオプロセシング特性のための、治療用免疫グロブリンｇ４の設計
US11542337B2 (en) 2016-12-23 2023-01-03 Bristol Myers Squibb Company Therapeutic immunoglobulin G4 for improved bioanalytical and bioprocessing properties
JP7432650B2 (ja) 2016-12-23 2024-02-16 ブリストル－マイヤーズ スクイブ カンパニー 改善されたバイオアナリシス特性およびバイオプロセシング特性のための、治療用免疫グロブリンｇ４の設計
JP2022109960A (ja) * 2016-12-23 2022-07-28 ブリストル－マイヤーズ スクイブ カンパニー 改善されたバイオアナリシス特性およびバイオプロセシング特性のための、治療用免疫グロブリンｇ４の設計
JP2020504608A (ja) * 2016-12-23 2020-02-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善されたバイオアナリシス特性およびバイオプロセシング特性のための、治療用免疫グロブリンｇ４の設計
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
US12024560B2 (en) 2017-03-28 2024-07-02 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
US12600798B2 (en) 2017-03-31 2026-04-14 Public University Corporation Nara Medical University Medicinal composition usable for preventing and/or treating blood coagulation factor IX abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor VIII
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US12509511B2 (en) 2017-05-02 2025-12-30 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
JP2023055821A (ja) * 2017-10-18 2023-04-18 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
JP2021500024A (ja) * 2017-10-18 2021-01-07 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
JP7530457B2 (ja) 2017-10-18 2024-08-07 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
JP2024103596A (ja) * 2017-10-18 2024-08-01 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
US11613566B2 (en) 2017-10-18 2023-03-28 Alpine Immune Sciences, Inc. Variant ICOS ligand immunomodulatory proteins and related compositions and methods
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019077092A1 (en) 2017-10-20 2019-04-25 F. Hoffmann-La Roche Ag METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
WO2019086362A1 (en) 2017-10-30 2019-05-09 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies
US12421322B2 (en) 2017-11-01 2025-09-23 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
US12428496B2 (en) 2017-12-07 2025-09-30 Chugai Seiyaku Kabushiki Kaisha Antibodies, compositions for use in detecting or capturing a polypeptide in a sample, and methods for detecting or capturing a polypeptide in a sample
US12600772B2 (en) 2018-01-31 2026-04-14 Motokazu Kato Therapeutic agent for asthma containing IL-6 inhibitor
US11891432B2 (en) 2018-03-15 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
WO2019225568A1 (ja) 2018-05-21 2019-11-28 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
JP2023168526A (ja) * 2018-07-10 2023-11-24 国立大学法人神戸大学 抗ＳＩＲＰα抗体
US12486329B2 (en) 2018-07-10 2025-12-02 National University Corporation Kobe University Anti-SIRPα antibody
WO2020032230A1 (ja) 2018-08-10 2020-02-13 中外製薬株式会社 抗ｃｄ１３７抗原結合分子およびその使用
JP2024009224A (ja) * 2019-04-04 2024-01-19 小野薬品工業株式会社 二重特異性抗体
JP7688805B2 (ja) 2019-04-04 2025-06-05 小野薬品工業株式会社 二重特異性抗体
US12325746B2 (en) 2019-04-04 2025-06-10 Ono Pharmaceutical Co., Ltd. Bispecific antibody
WO2020204152A1 (ja) * 2019-04-04 2020-10-08 小野薬品工業株式会社 二重特異性抗体
WO2020209318A1 (ja) 2019-04-10 2020-10-15 中外製薬株式会社 Ｆｃ領域改変抗体の精製方法
US12583918B2 (en) 2019-04-17 2026-03-24 Tokyo Women's Medical University Therapeutic agent for urological cancer which is characterized by being administered with IL-6 inhibitor and CCR2 inhibitor in combination
US12528863B2 (en) 2019-07-10 2026-01-20 Chugai Seiyaku Kabushiki Kaisha Claudin-6 binding molecules and uses thereof
US12171830B2 (en) 2019-11-20 2024-12-24 Chugai Seiyaku Kabushiki Kaisha Anti-IL-31RA antibody-containing formulations
US11723976B2 (en) 2019-11-20 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Methods of administering anti-IL31A antibody-containing formulations
US11260125B2 (en) 2019-11-20 2022-03-01 Chugai Seiyaku Kabushiki Kaisha Anti-IL31RA antibody-containing formulations
US11739142B2 (en) 2019-12-18 2023-08-29 Hoffmann-La Roche Inc. Bispecific anti-CCL2 antibodies
US12103967B2 (en) 2019-12-18 2024-10-01 Hoffmann-La Roche Inc. Bispecific anti-CCL2 antibodies
WO2021122733A1 (en) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
WO2021131021A1 (ja) 2019-12-27 2021-07-01 中外製薬株式会社 抗ｃｔｌａ－４抗体およびその使用
WO2021162020A1 (ja) 2020-02-12 2021-08-19 中外製薬株式会社 癌の治療に用いるための抗ｃｄ１３７抗原結合分子
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
WO2022025030A1 (ja) 2020-07-28 2022-02-03 中外製薬株式会社 新規改変型抗体を含む、針シールドを備えた針付プレフィルドシリンジ製剤
WO2022045276A1 (ja) 2020-08-28 2022-03-03 中外製薬株式会社 ヘテロ二量体Ｆｃポリペプチド
JP2022060182A (ja) * 2020-10-02 2022-04-14 小野薬品工業株式会社 二重特異性抗体を有効成分として含む医薬組成物
JP7714992B2 (ja) 2020-10-02 2025-07-30 小野薬品工業株式会社 二重特異性抗体を有効成分として含む医薬組成物
WO2022263501A1 (en) 2021-06-18 2022-12-22 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
WO2022270612A1 (ja) 2021-06-25 2022-12-29 中外製薬株式会社 抗ｃｔｌａ－４抗体の使用
US12415857B2 (en) 2021-06-25 2025-09-16 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
WO2022270611A1 (ja) 2021-06-25 2022-12-29 中外製薬株式会社 抗ｃｔｌａ－４抗体
WO2023057871A1 (en) 2021-10-04 2023-04-13 Novartis Ag Surfactant stabilizers
WO2023058723A1 (ja) 2021-10-08 2023-04-13 中外製薬株式会社 プレフィルドシリンジ製剤の調製方法
WO2023100975A1 (ja) 2021-12-01 2023-06-08 中外製薬株式会社 抗体含有製剤の調製方法
WO2023210670A1 (ja) 2022-04-26 2023-11-02 中外製薬株式会社 医薬製剤含有フィルター内蔵シリンジ
JP7820529B2 (ja) 2022-08-10 2026-02-25 協和キリン株式会社 抗ｆｇｆ２３抗体又は該抗体断片
WO2024034638A1 (ja) * 2022-08-10 2024-02-15 協和キリン株式会社 抗ｆｇｆ２３抗体又は該抗体断片
JPWO2024034638A1 (https=) * 2022-08-10 2024-02-15
US12606615B2 (en) 2022-08-10 2026-04-21 Kyowa Kirin Co., Ltd. Anti-FGF23 antibody or antibody fragment thereof
WO2024214811A1 (ja) 2023-04-14 2024-10-17 中外製薬株式会社 タンパク質含有医薬製剤の安定化方法
US12617872B2 (en) 2025-09-16 2026-05-05 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications

Also Published As

Publication number Publication date
MY193526A (en) 2022-10-18
KR20160135850A (ko) 2016-11-28
CA2700394A1 (en) 2009-04-02
PH12018501459B1 (en) 2024-06-28
PE20090711A1 (es) 2009-07-15
CA2978687C (en) 2020-02-18
CL2008002886A1 (es) 2009-12-04
JPWO2009041613A1 (ja) 2011-01-27
AU2008304748A1 (en) 2009-04-02
KR20210024260A (ko) 2021-03-04
CA2700394C (en) 2017-10-24
KR102467302B1 (ko) 2022-11-14
SG193868A1 (en) 2013-10-30
JP5930503B2 (ja) 2016-06-08
EP3789400A1 (en) 2021-03-10
AR110887A2 (es) 2019-05-15
KR20180126633A (ko) 2018-11-27
HK1146728A1 (en) 2011-07-08
TW201429986A (zh) 2014-08-01
MX342551B (es) 2016-10-04
EP2194066B1 (en) 2016-03-09
KR102119108B1 (ko) 2020-06-04
CA3139492A1 (en) 2009-04-02
AR068563A1 (es) 2009-11-18
KR20100074221A (ko) 2010-07-01
JP2016026215A (ja) 2016-02-12
JP2019001794A (ja) 2019-01-10
ES2687808T3 (es) 2018-10-29
CA3066453C (en) 2022-01-11
IL204537A0 (en) 2010-11-30
RU2010116278A (ru) 2011-11-10
JP2022101707A (ja) 2022-07-06
DK2194066T3 (en) 2016-05-02
KR101922788B1 (ko) 2018-11-27
RU2014122609A (ru) 2015-12-10
PH12014502106B1 (en) 2015-12-07
EP2194066A1 (en) 2010-06-09
US9688762B2 (en) 2017-06-27
KR102225009B1 (ko) 2021-03-08
JP2014144956A (ja) 2014-08-14
KR102339457B1 (ko) 2021-12-14
EP2194066A4 (en) 2010-12-15
PH12021552811A1 (en) 2022-11-21
PH12018501459A1 (en) 2019-11-11
CN101874041A (zh) 2010-10-27
CA3066453A1 (en) 2009-04-02
CA3139492C (en) 2024-04-30
EP3059246B1 (en) 2018-07-11
JP7072032B2 (ja) 2022-05-19
TWI464262B (zh) 2014-12-11
RU2526512C2 (ru) 2014-08-20
ZA201002422B (en) 2014-06-25
JP2021020949A (ja) 2021-02-18
MY180713A (en) 2020-12-07
JP6385386B2 (ja) 2018-09-05
MY163473A (en) 2017-09-15
US12600789B2 (en) 2026-04-14
SG10201605394SA (en) 2016-08-30
PL3059246T3 (pl) 2018-11-30
US20100298542A1 (en) 2010-11-25
JP5484060B2 (ja) 2014-05-07
EP3059246A1 (en) 2016-08-24
PH12014502106A1 (en) 2015-12-07
TW200925273A (en) 2009-06-16
JP2025128348A (ja) 2025-09-02
EP3415529A1 (en) 2018-12-19
JP2024012685A (ja) 2024-01-30
US11332533B2 (en) 2022-05-17
MX2010003450A (es) 2010-04-27
CA2978687A1 (en) 2009-04-02
KR101680906B1 (ko) 2016-11-30
AU2008304748C1 (en) 2014-06-12
TWI563002B (en) 2016-12-21
US20220251225A1 (en) 2022-08-11
BRPI0817273A2 (pt) 2015-06-16
KR20200062390A (ko) 2020-06-03
JP5868441B2 (ja) 2016-02-24
KR20210156290A (ko) 2021-12-24
DK3059246T3 (en) 2018-10-01
ES2566957T3 (es) 2016-04-18
EP3415529B1 (en) 2020-11-04
US20170342154A1 (en) 2017-11-30
AR110822A2 (es) 2019-05-08
AR117007A2 (es) 2021-07-07
AU2008304748B2 (en) 2014-01-16
CA3222170A1 (en) 2009-04-02
JP2016169220A (ja) 2016-09-23
CN101874041B (zh) 2013-06-19

Similar Documents

Publication Publication Date Title
WO2009041613A1 (ja) 抗体定常領域改変体
MY162534A (en) Anti-il-6 receptor antibody
WO2007041635A3 (en) Fc variants with optimized fc receptor binding properties
DK1765860T3 (da) Ny-ESO-T.cellereceptor med höj affinitet
WO2004113387A3 (en) Tumour necrosis factor receptor molecules with reduced immunogenicity
WO2008094538A3 (en) Regulatory t cell epitopes, compositions and uses thereof
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
WO2011032161A8 (en) Vaccines directed to langerhans cells
NZ600348A (en) Anti-c5a binding moieties with high blocking activity
WO2004063963A3 (en) Novel proteins with altered immunogenicity
WO2013115926A3 (en) Aspartyl-trna synthetase-fc conjugates
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
NZ600278A (en) Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
WO2007134876A3 (en) HIGH AFFINITY HUMAN AND HUMANIZED ANTI-α5β1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY
WO2009022157A3 (en) Peptide with improved solubility
WO2009109635A3 (en) Novel antigen binding dimer-complexes, methods of making and uses thereof
NZ612312A (en) Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota
WO2008005880A3 (en) Antibodies for norovirus
WO2006046978A3 (en) Cationic peptide-mediated transformation
WO2007067597A3 (en) Methods and compositions for needleless delivery of binding partners
WO2010006343A3 (en) Glycopeptide constructs and uses thereof
WO2005051999A3 (en) Substance binding human igg fc receptor iib
DE602008005857D1 (de) Neue antimalaria-impfstoffzusammensetzungen und anwendungen davon
WO2005076972A3 (en) Chimeric vegf peptides
WO2008055972A3 (en) N-terminal pegylated prolactin receptor molecules

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880118581.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08834649

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009534420

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 204537

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2700394

Country of ref document: CA

Ref document number: 2008304748

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12010500632

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2101/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/003450

Country of ref document: MX

Ref document number: 2008834649

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008304748

Country of ref document: AU

Date of ref document: 20080926

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107008918

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010116278

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: PI 2010001335

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 12680082

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0817273

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100326

WWE Wipo information: entry into national phase

Ref document number: IDP00201605333

Country of ref document: ID

Ref document number: IDP00201605334

Country of ref document: ID

WWE Wipo information: entry into national phase

Ref document number: 12018501459

Country of ref document: PH